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Abstract
Background: The Basque Colorectal Cancer Screening Programme began in 2009 and the implementation has been
complete since 2013. Faecal immunological testing was used for screening in individuals between 50 and 69 years old.
Colorectal Cancer in Basque country is characterized by unusual epidemiological features given that Colorectal Cancer
incidence is similar to other European countries while adenoma prevalence is higher. The object of our study was to
economically evaluate the programme via cost-effectiveness and budget impact analyses with microsimulation models.
Methods: We applied the Microsimulation Screening Analysis (MISCAN)-Colon model to predict trends in Colorectal
Cancer incidence and mortality and to quantify the short- and long-term effects and costs of the Basque Colorectal
Cancer Screening Programme. The model was calibrated to the Basque demographics in 2008 and age-specific Colorectal
Cancer incidence data in the Basque Cancer Registry from 2005 to 2008 before the screening begun. The model was also
calibrated to the high adenoma prevalence observed for the Basque population in a previously published study. The
multi-cohort approach used in the model included all the cohorts in the programme during 30 years of implementation,
with lifetime follow-up. Unit costs were obtained from the Basque Health Service and both cost-effectiveness analysis and
budget impact analysis were carried out.
Results: The goodness-of-fit of the model adaptation to observed programme data was evidence of validation. In the
cost-effectiveness analysis, the savings from treatment were larger than the added costs due to screening. Thus, the
Basque programme was dominant compared to no screening, as life expectancy increased by 29.3 days per person. The
savings in the budget analysis appeared 10 years after the complete implementation of the programme. The average
annual budget was €73.4 million from year 2023 onwards.
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Conclusions: This economic evaluation showed a screening intervention with a major health gain that also produced
net savings when a long follow-up was used to capture the late economic benefit. The number of colonoscopies
required was high but remain within the capacity of the Basque Health Service. So far in Europe, no other population
Colorectal Cancer screening programme has been evaluated by budget impact analysis.
Keywords: Colorectal Cancer, Mass screening, Cost-effectiveness analysis, Budget impact analysis
Background
The cost effectiveness of colorectal cancer (CRC) screen-
ing has been widely documented [1–4]. However, spe-
cific evaluations for different programmes are necessary
because local CRC epidemiology (cancer incidence and
adenoma prevalence) and the actual implementation of
screening (type of test, attendance rate, and surveillance
schedule) can cause variations in efficiency [4–6]. CRC
in Basque country is characterized by unusual epidemio-
logical features given that CRC incidence is similar to
other European countries while adenoma prevalence is
higher [7]. Therefore the need for independent evalu-
ation is especially noteworthy. As with all public health
interventions, cancer screening programmes must meas-
ure their value, i.e., the health outcomes achieved per
euro spent for the whole population [8, 9].
The Basque CRC Screening Programme began in 2009
at the suggestion of the Cancer Advisory Council, which
took into account the significant increase of both CRC
incidence and mortality in the Basque Country from
1986 through 2008 [10–12]. Like most European pro-
grammes, it uses faecal immunochemical testing (FIT)
to detect microscopic bleeding from adenomas or pre-
clinical CRC [10, 13]. Individuals with positive test
results are referred for a diagnostic colonoscopy and
can then be assigned to a surveillance schedule [13].
As more cohorts are included in the programme, the
number of colonoscopies grows, and programme feasi-
bility relies on its capacity to respond to that demand
[3, 5, 14]. The Basque CRC epidemiology of high aden-
omas prevalence may constitute a challenge because it may
mean that the number of colonoscopies required in the
CRC screening programme will be higher. Experts have
underscored the need to tailor the implementation of CRC
screening in populations within the context of organized
programmes [6, 15].
During the first four years of implementation, the
Basque programme performed 295,934 screening tests,
and 17,146 diagnostic colonoscopies were carried out to
confirm positive FIT results. Such marked resource con-
sumption alone justifies conducting an economic assess-
ment that takes into account the results in the middle
and long term [5, 9]. Besides the cost effectiveness, for a
comprehensive economic evaluation, it is essential ana-
lysing the programme’s affordability regarding the global
budget impact [16]. This analysis addresses the expected
changes in the expenditure of a healthcare system after
the adoption of a new intervention [16]. As with other
CRC screening programmes, sustainability analysis must
also tackle the demand for colonoscopies to avoid future
inability to meet the need [2–6, 15]. To carry out the eco-
nomic evaluation of cancer screening programmes, wide-
spread use of decision models has been the rule generally,
[2–6] as well as in the Basque Country [17, 18].
Because the implementation of the Basque CRC
programme has been complete since 2013, decision-
makers should now be informed as to whether the resources
are appropriately allocated and the programme is sustain-
able given the high prevalence of adenomas. The object of
our study was to economically evaluate the programme
compared to no screening via cost-effectiveness and budget
impact analyses with microsimulation models calibrated to
the Basque epidemiological features of CRC incidence and
adenoma prevalence [11, 19, 20].
Methods
As the programme targeted the population between 50
and 69 years of age and used biennial FIT screening and
complete colonoscopy to confirm positive results, its
evaluation required follow-up of the target population at
middle and long term. To estimate the economic results
of the screening strategy implemented in the Basque
Country, the Microsimulation Screening Analysis model
for colorectal cancer (MISCAN-Colon) was applied.
MISCAN-Colon is a stochastic microsimulation model for
colorectal cancer (CRC) developed using Delphi program-
ming language (Borland Software Corporation, Scotts
Valley, California, United States). The aim of the model
was to explain and predict CRC incidence and mortality
trends, as well as, assessing the effect of primary preven-
tion of CRC, screening for CRC, and surveillance after
polypectomy in terms of both health and costs. The struc-
ture of the MISCAN-Colon model and the sources that
inform the parameters of the model have been fully de-
scribed in previous publications, [21–25] as well as in a
standardised model profile of the Cancer Intervention and
Screening Network (CISNET) [26]. A full description of
the model was also included in the Model Appendix sec-
tion of the Additional file 1.
Arrospide et al. BMC Cancer  (2018) 18:464 Page 2 of 11
Individuals of a large population were simulated using
MISCAN-Colon. They were created at birth and lifelong
follow-up was applied. Natural history of CRC was in-
cluded according to the adenoma–carcinoma sequence
[27, 28]. The model assumes the possibility for more than
one adenoma at the same time in each individual. Each
adenoma can independently progress in size (≤5 mm, 6–
9 mm, ≥10 mm) and develop into CRC. In addition, some
will become malignant, transforming to stage I CRC; some
cases of CRC may even progress to more advanced stages.
At any stage, CRC may be diagnosed due to the develop-
ment of symptoms. When CRC finally develops, the sur-
vival rate after diagnosis depends on the stage at which
the cancer was detected. In addition, at any time during
the individual’s life, the process may be interrupted by his/
her death from other causes. With this model, the entire
target population can be followed from birth to death to
measure both the long-term costs and health outcomes
related to the programme.
Simulated population
We reproduced the entire Basque population in 2008:
2,230,000 people, 51% women. The screening programme
begun in 2009 was fully implemented by 2013. In order to
reproduce the implementation strategy, the population
was divided into different strata based on its age structure
and the calendar year at which individuals were invited
into the programme for the first time (or never invited in
the event that they were 70 or older in 2009). In the model
the continuation of the screening programme was set to
30 years (2009–2038). In this way the model enabled the
evaluation of the screening as a public health intervention
by estimating both lifetime costs and health benefits.
Table 1 shows the data and sources used in the model.
This study was approved by the Basque Country’s Ethics
Committee.
As the MISCAN-Colon model was developed within
the CISNET group, [26] it was first calibrated to CRC
epidemiology and demographics of the United States
population. Therefore, to use it for the Basque population,
the age-specific CRC incidence by location (colon and rec-
tum) and stage distribution were calibrated to the incidence
data from the Basque Cancer Registry for the years 2005–
2008, prior to the implementation of the CRC screening
programme. Simultaneously, the MISCAN-Colon model
was calibrated to the adenoma detection rates calculated
for the Basque population from the COLONPREV study
[20]. Separate models were built for men and women
due to epidemiological differences in the natural history
of CRC.
Screening scenario simulated
Screening was simulated according to the design of
the Basque colorectal cancer screening programme.
All individuals within the programme’s age range biennially
received an invitation letter that included a FIT. Delivering
a sample to the assigned primary care health centre was
necessary to have it analysed for microscopic bleeding. The
cut-off was established at 20 μg/g faeces. Those participants
with a positive test result were referred for colonoscopy.
Furthermore, patients with at least one adenoma > 20 mm
or five or more adenomas were recalled within a year
for a surveillance colonoscopy and those with one ad-
enoma > 10 mm or more than three adenomas or any
adenomas with a villous component or high degree of
dysplasia were invited for surveillance colonoscopy in
three years, and all individuals with adenomas < 10 mm
or 1 to 2 adenomas or tubular component or low degree of
dysplasia were invited for regular FIT screening in 5 years.
All recommendations were based on the European surveil-
lance guidelines [13] adapted to the size-dependent classifi-
cation in the model. A description of the surveillance
protocol appears in the Additional file 2: Table S1. Partici-
pation rates both for FIT and colonoscopy were estimated
for initial and successive invitations, depending on the
individual’s age as determined by available data from
the Basque CRC Screening Programme in the period
2009–2012 (Table 1).
Test characteristics
Test characteristics were fitted to the positivity and detec-
tion rates of advanced neoplasia observed in the Basque
programme between 2011 and 2012 (Additional file 2:
Table S2). Advanced neoplasia included CRC and advanced
adenomas, which were defined as adenomas ≥10 mm in
size, with a 25% or greater villous component and/or high-
Table 1 Sources of parameters used in the adaptation of the
MISCAN-Colon model to the Basque population and screening
programme
Data Source
Demographics 2008 EUROSTAT – Basque Institute of
Statistics
CRC incidence 2005–2008 Basque Cancer registry




Costs screening Basque CRC screening programme
Costs colonoscopy Basque Health Service accounting
system
Costs treatment Basque Health Service accounting
system
Utilities [30]
Invitations 2009–2013 Basque CRC screening programme
Participation 2009–2012 Basque CRC screening programme
Test features 2011–2012 Basque CRC screening programme
EUROSTAT Statistical Office of the European Union, CRC colorectal cancer
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grade dysplasia. The screening module was tested by repro-
ducing invitations, participation and test results.
After the natural history of CRC without detection by
screening was reproduced, the behaviour of CRC was
reproduced according to the screening scenario, in which
the impact of removing adenomas and anticipation of the
CRC stage at diagnosis were considered. Those conse-
quences were translated in quality-adjusted life years
(QALY) gained and avoided costs in treatment.
Costs and utilities
We applied the perspective of the Basque Health Ser-
vice, which is responsible for delivering screening to
the entire Basque population between 50 and 69 years
old. Unit costs were obtained in Euros (Sep 2012: 1
Euro = 1.25 US dollars) from the accounting systems in
the service. The resources assigned to each screened
person were disaggregated by invitation (€6.06 includ-
ing invitation letter, FIT and programme management
resources), FIT analysis in participants (€0.99), primary
care consultation in case of positive results (€78.00)
and colonoscopies (€461.30 with polypectomy and €281.30
without polypectomy). We also applied an average cost of
€5157.00 for complications related to colonoscopy. To cal-
culate the costs of CRC treatment, we retrospectively col-
lected stage and resource use from a sample of 529
patients [29]. For stages I to III the initial and follow-
up costs were measured. The calculation of cost for
stage IV disease combined generalized linear models
to relate the cost to the duration of follow-up on the
basis of parametric survival analysis. Unit costs were
obtained from the analytical accounting system of the
Basque Health Service. The sample included 110 cases
in stage I, 171 in stage II, 158 in stage III and 90 in
stage IV. The initial total cost ranged from €6968 for
stage I to €12,765 for stage II and €13,075 for stage
III. The estimation of the annual cost for follow-up
care included computed tomography, colonoscopy,
tests and external consultations, and an amount of
€404 was rendered. For those patients in stage IV spe-
cific initial treatment cost was not considered, how-
ever, the cost for each year of follow-up was €24,255.
The details of the generalized linear model are re-
ported in the Additional file 2: Table S3.
As specific preference values for the different stages of
CRC were not available for the Basque or Spanish popu-
lation, we incorporated utilities that were already in the
MISCAN-Colon model (Additional file 2: Table S4) [29].
We assumed a utility loss (i.e., a loss of QALY) equiva-
lent to two full days of life per colonoscopy (0.0055
QALY) and two weeks of life per complication (0.0384
QALY). We also assigned a utility loss to each life-year
with CRC care (Additional file 2: Table S4) [30].
Economic evaluation
The economic evaluations included both the cost-
effectiveness analysis and the budget impact analysis
(BIA) of the programme from the perspective of the
Basque Health System. The evaluation period was defined
as 2009 through December 31, 2038. The incremental
cost-effectiveness ratio (ICER) incorporated the additional
QALY gained in the denominator and the additional costs
incurred by the programme in the numerator [9]. We ap-
plied a multi-cohort approach by including all the cohorts
in the programme during 30 years of implementation
from its beginning in 2009. After this period, from 2039
onwards, the programme did not include more cohorts,
but maintained the intervention for all individuals already
included in the screening programme. The entire popula-
tion had lifetime follow-up in order to capture the long-
term impact. Costs and QALYs were discounted by 3%.
The microsimulation model was used simultaneously for
BIA. The annual costs for CRC diagnosis and treatment in
both the screened and unscreened populations from 2009
to 2038 were calculated in the model [16, 18]. Diagnostic
resources included screening tests (FIT and diagnostic and
surveillance colonoscopies) and clinical colonoscopies
implemented in the reference hospital. It was not ne-
cessary to discount the costs because the BIA showed
financial streams over time without aggregation [16].
Sensitivity analysis
To assess the impact of model assumptions in our results,
three main sensitivity analyses were carried out: 1) A sce-
nario including a lower prevalence of adenomas based on
the literature [31–40] was run in addition to the base case
model; 2) Because individuals with a false negative test re-
sult have a higher than average probability of another false
negative test result at a successive screening, we also devel-
oped a new scenario in which dependency of FIT results in
sequential screening rounds was assumed (Additional file 2:
Table S2) [41]; 3) The impact of increasing the cost of
screening was also estimated.
Results
Goodness-of-fit
Goodness-of-fit obtained in the MISCAN-Colon model
adaptation for adenoma prevalence by age and gender,
respectively, is shown in Fig. 1a and b and Model
Appendix contain further validation details such as
CRC incidence fitting. The model showed good concord-
ance with the number of diagnostic colonoscopies ob-
served in the Basque programme from 2009 to 2014
(Fig. 2a and b), validating the base scenario of high
adenoma prevalence. Only in 2013 observed participa-
tion and positivity rates exceeded those simulated and
the number of diagnostic colonoscopies carried out in
the programme was also higher than forecasted. In 2014
Arrospide et al. BMC Cancer  (2018) 18:464 Page 4 of 11
the fit was better. Some other internal validation results,
such as invitations and adherence to the programme
and FIT characteristics in the period 2009–2014 were
also used to validate model fitting and prediction behav-
iour (Additional file 2: Figure. S1 and Additional file 2:
Figure S2). All these comparisons pointed to the good fit
achieved in the adaptation of the MISCAN-Colon model
to the Basque population and screening programme.
Cost-effectiveness analysis
Without screening, the target Basque population in 2008
was expected to live on average 41.1 years (Table 2).
After the implementation of the screening programme,
that life expectancy increased by 29.3 days per person.
This gain in terms of life-years involved an incremental
effectiveness of 56,664.8 QALY (with 3% discount) due
to screening. The total cost for screening, diagnostic
follow-up, surveillance and treatment, during the applied
time horizon, was €2057.2 million (Table 2). However, be-
cause screening resulted in a substantial reduction of colo-
rectal cancer incidence, there was a large reduction in the
costs of treating CRC (256.3 m€) and a net saving of €93.1
million (Table 2) compared to that in the unscreened popu-
lation. Overall, these savings from treatment were larger
Fig. 1 Adenomas Prevalence Observed in COLONPREV study and other published studies Versus Simulated by MISCAN-Colon (% of individuals
with adenomas)*. a) Men; b) Women. *Observed results are only shown for the two largest studies on which the model has been calibrated.
MISCAN-Colon has additionally been calibrated to 8 other autopsy studies
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than the costs for screening, and thus, the Basque screening
programme was dominant compared to no screening.
Budget impact analysis
Total and incremental costs related to screening, diagnosis
and treatment of CRC in both scenarios (screened and un-
screened) are displayed by year in Fig. 3. High screening
costs due to the high number of positive test results for
prevalent adenomas and cases of CRC were involved in
the first four years after the introduction of screening until
2013, when 100% implementation was achieved. During
the first five years of implementation, €69.2 million were
necessary on average to annually fund the screening
(Fig. 3 and Additional file 2: Table S5). The savings in
the BIA appear in 2023, 10 years after the complete
implementation of the programme. Even though the sav-
ings from screening were small at first, they increased as
the impact of the programme became apparent. Figure 3
Fig. 2 Predicted number of diagnostic and total colonoscopies needed each year in base-case scenario. a) Independent successive screening
tests; b) Correlated successive screening tests. Diag: diagnostic; CSC: colonoscopies
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Table 2 Sensitivity analysis for cost-effectiveness analysis of the implementation of colorectal cancer screening programme in the
Basque population
Screened population costs Incremental costs QALYs gained ICER
Cost per invitation Adenoma prevalence Treatment cost Total costs Treatment cost Total costs
€6.06 per invitation Base case
Men 1199.9 1317.0 −179.1 −81.7 37,132.5 Dominant
Women 664.2 740.2 −77.1 −11.4 19,532.3 Dominant
Total 1864.1 2057.2 −256.3 −93.1 56,664.8 Dominant
Prevalence Bibliography
Men 1227.5 1318.9 −168.6 −97.2 36,616.9 Dominant
Women 661.0 726.9 −77.6 −21.8 20,438.5 Dominant
Total 1888.5 2045.7 − 246.2 −119.0 57,055.4 Dominant
€15.00 per invitation Base case - Total 1864.1 2103.2 −256.3 −47.1 56,664.8 Dominant
€20.00 per invitation Base case - Total 1864.1 2128.9 −256.3 −21.4 56,664.8 Dominant
€25.00 per invitation Base case - Total 1864.1 2154.6 −256.3 4.2 56,664.8 74.1
€30.00 per invitation Base case - Total 1864.1 2180.3 −256.3 30.0 56,664.8 529.4
€40.00 per invitation Base case - Total 1864.1 2231.8 −256.3 81.5 56,664.8 1438.3
€50.00 per invitation Base case - Total 1864.1 2283.2 −256.3 132.9 56,664.8 2345.4
ICER incremental cost effectiveness ratio
Fig. 3 Budget impact analysis for base case scenario
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shows that the increase in the annual budget for the age-
ing unscreened population disappeared when screening
was applied, and thus a stable annual budget of €73.4
million was achieved on average from year 2023 onwards.
In addition, the model predicted the number of colon-
oscopies during a 30-year period (Fig. 2), which reached
a maximum in 2032 with 19,384. On average, the esti-
mated annual number of colonoscopies (including diag-
nostic, surveillance and clinical colonoscopies) needed in
the base case from 2029 through 2038 was 18,843 (52.5%
surveillance colonoscopies).
Sensitivity analysis
When a scenario with lower adenoma prevalence was set,
the number of colonoscopies declined to 14,167 (Additional
file 1: Figure. S3) and the net cost savings amounted to
€119 million in the study period (Additional file 1:
Figure. S4). Similarly, when the possibility of systematic
false negative test results was included in the model, it
was determined that fewer colonoscopies (16,605) than
estimated for the base case were necessary and involved a
savings of €95.1 million compared to the no-screening
scenario. Finally, when unit costs for screening invitations
were increased, the model showed that the screening
programme would remain cost-saving if the cost of an in-
vitation remained ≤20€ per invitation (€21.4 million saved)
(Table 2).
Discussion
This cost-effectiveness analysis featured the Basque CRC
screening programme as a dominant intervention because
it produced net cost savings and health benefits [9]. Budget
analysis also showed a consistent savings after 10 years of
its complete implementation, highlighting the afford-
ability of the programme [16]. Both approaches to eco-
nomic evaluation reveal that only a long follow-up is
able to capture the late economic benefit of the screening
based on the decrease in the number of cases of CRC in
early and advanced stages and the consequent reduction
in need for treatment. So far in Europe, no other
population-based CRC screening programme has been
evaluated with a comprehensive approach including
both cost-effectiveness and budget impact analysis to
prove the programme’s efficiency and affordability. Obvi-
ously, our results support the continuity of this preventive
policy for CRC. Two literature reviews confirmed this find-
ing, emphasising that colorectal cancer screening is cost ef-
fective or dominant compared with no screening [42, 43].
Public health programmes must be reappraised period-
ically to confirm that they have achieved planned results
[44]. Modelling can also be useful in other countries to
inform the population programme planning. Our sensitivity
analysis showed the impact of the actual adenoma preva-
lence on the need of colonoscopies. A realistic estimation
for the number of colonoscopies needed could be made
based on the early report produced by the COLONPREV
study [20].
Different strategies for CRC screening are supported
by the evidence. As the Basque programme is based on
FIT, our assessment cannot avoid comparison with an
alternative approach based on colonoscopy as the first
test, which is the norm in the United States. To make
that comparison, however, the number of colonoscopies
required for effective screening must be considered. Any
evaluation must assess if a health system has the capacity to
absorb such increased demand for screening colonoscopies.
Typically, when the demand exceeds the capacity to deliver,
the implementation of the programme is obstructed.
Moreover, the required number of colonoscopies is dir-
ectly related to the prevalence of adenomas in the specific
population [14, 19]. In our study, this indicator was espe-
cially noteworthy because the adenoma prevalence in the
Basque sample of the COLONPREV study yielded a higher
number than that used in the MISCAN-Colon model [20].
The consequence of this finding could jeopardize the
sustainability of the programme. The higher prevalence
showed that 4200 more colonoscopies annually were
necessary on average than were needed in the scenario
based on a low prevalence. Both numbers were lower in
the scenario in which dependency of FIT results in se-
quential screening rounds was assumed, that is, taking
into account that individuals with a false negative test
result have a higher than average probability of another
false negative test result at a successive screening [41].
These predicted figures highlight the sustainability of
the programme in operational terms, because the num-
ber of necessary diagnostic colonoscopies stabilized at
approximately 8000, which was the number already
being delivered. However, the maximum capacity of the
Basque Health System to carry out screening colonos-
copies has been reached. Thus, any other proposal for
CRC screening that led to more colonoscopies would
not be feasible with the currently available resources.
As colonoscopies delivery become usually a bottleneck
in the process of implementing CRC screening.
To explain the long-term cost savings, we need to
underline that although the screening programme and the
derived colonoscopies meant a significant expense, more
than 90% of the total expenditure originated with treat-
ment costs. To reach this conclusion, future results had to
be predicted. So, although the number of required colon-
oscopies rose with increasing prevalence of adenomas, the
impact on the total cost was limited [20, 31]. The total
costs in the unscreened scenario grew steadily during the
analysed years because the number of CRC cases in the
Basque population rose with the aging of the baby
boomers. The main component of those costs was the
treatment costs that were proportional to the incidence.
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It is noteworthy that screening impact meant stabilization
in total costs because the raw incidence was maintained
and, therefore, the CRC age-adjusted rates decreased.
Decision-making on the basis of models is not without
limitations. Although we used a model of high quality
(MISCAN-Colon), which was adjusted to the epidemi-
ology of the Basque population and the characteristics of
the programme, model calibration was meant to force
some parameters such as the classification of adenomas.
The programme information system categories are risk-
based, whereas the MISCAN-Colon model sorts them by
size. The problem was resolved by reclassifying the aden-
omas found in the programme according to size. We
understand that this adjustment did not involve any threat
to the validity of the results, given the exhaustive process of
calibration and validation. In addition, only costs related to
the screening programme and CRC treatment were consid-
ered in the analysis; thus, we did not take into account the
of cost of care of unrelated diseases that could appear due
to increasing survival time. Including these costs could
increase the final ICER and reduced the efficiency of the
screening. Finally, the model did not include a probabilistic
sensitivity analysis that is the norm in pharmacoeconomics,
because of the difficulty of the computational burden in
public health studies in which required dynamic models
can include millions of individuals. However, the thorough
calibration algorithm in MISCAN-Colon and the compre-
hensive internal and external validation warrant its robust-
ness and, therefore, the reliability of the results.
Some of the differing results achieved in cost-effectiveness
studies have been attributed to the dissimilarities in struc-
ture and parameters of the models applied to follow the
entire life of the target population. The natural history of
CRC as represented by the MISCAN-Colon model is shared
by other CISNET partners, and its consistency has been
fully proven [45, 46]. Moreover, the calibration of the
MISCAN-Colon model to fit the epidemiology of CRC
and adenoma prevalence in the Basque country was
achieved by internal and external validation. As Patel et
al. pointed out, preclinical time, screening unit costs in
each setting or screening adherence, none of which is
the same in all studies, can explain heterogeneous re-
sults [43]. Good intermediate indicators of programme
performance, such as participation rate (64.3% in 2009–
2011) and waiting time for colonoscopy (30 days), also
show that the programme is on track and help to ex-
plain the final economic saving [10, 47]. Significantly,
that conclusion was also valid when the unit cost of
screening was doubled.
It is also important to put into context the relative
costs of the screening programme, as they represented
between 6% and 8% of the total cost, when we aggregated
the costs of the whole follow-up. Furthermore, that per-
centage range will probably decrease, as treatment costs
tend to grow as a consequence of the introduction of new
drugs much more expensive than those currently on the
market [48]. As oncology drugs become less cost effective
because of rising prices over time [48], the role of prevent-
ive policies is enhanced. Thus, our results support the idea
that reinforcement of screening seems a plausible future
option. Consideration of inequalities in access to health
care also sustains investments in screening, rather than
treatment. Although differences by social class have been
found in the screening programme, it is easier to provide
disadvantaged groups with better access to screening ser-
vices than to provide the entire population with the latest
oncological drugs [49].
The BIA approach to economic evaluation is used less
often than the cost-effectiveness design, but it is a com-
plementary and useful tool to show financial streams
over time. Usually the trade-offs between incurred and
saved costs are shown with a short time horizon, but the
BIA easily allows the application of a long follow-up to
capture the full economic and health benefit of the
screening programme. This is consistent with the natural
history of CRC and has been underscored in the litera-
ture [5]. An extended period of time is required for the
impact of polypectomies on avoided deaths and cancer
treatments to manifest, and thus, the first years of the
programme can be misleading because the change in
natural history of CRC has not reached a steady state in
terms of the population [47].
Conclusions
We would like to emphasise that this evaluation reaffirms
for decision-makers that the allocated resources for main-
taining the programme are a worthwhile investment. This
economic evaluation showed a screening intervention with
a major health gain that also produced net savings when a
long follow-up was used to capture the late economic bene-
fit. Our results support the continuity of the Basque Colo-
rectal Cancer Screnning Programme. Due to the actual
adenoma prevalence reported in the COLONPREV study a
realistic estimation of the future need of colonoscopies was
necessary. The number of colonoscopies required was high
but remain within the capacity of the Basque Health
Service. So far in Europe, no other population Colorectal
Cancer screening programme has been evaluated by budget
impact analysis. Budget impact analysis highlighted the
affordability of the programme showing consistent savings
after 10 years of complete implementation.
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